Amgen CEO Discusses Weight Loss Drug Efficacy and Patient Persistence

Amgen's Weight Loss Drug (GOP-1)

• 💡 Amgen is developing a long-acting medicine for obesity and related conditions, potentially including type two diabetes.
• 🎯 The drug is being studied as a once-monthly injection, with potential for less frequent use, including every 8 weeks and quarterly.
• 🔑 Encouraging data has been shown for quarterly use, suggesting multiple ways to win for patients in managing and maintaining weight loss.

Addressing Patient Persistence

• ⚠️ A key challenge in the field is patient persistence, where individuals stop therapy, impacting long-term benefits.
• 📈 Amgen's studies have shown impressive weight loss over 52 weeks and are investigating methods to help patients maintain weight loss over the long term.
• 🔬 Research over 104 weeks aims to understand the appropriate dosing for weight loss maintenance and what encourages patients to stay on therapy.
• ✅ The benefit of the drug is directly tied to continued use of the therapy.